Serum soluble interleukin-2 (IL-2) receptor (sIL-2R) was discovered in supernatants of adult T-cell leukemia/lymphoma (ATLL) cell lines [1], and now has been recognized as a tumor-related biomarker of malignant lymphomas, including B-cell malignancies [2], [3]. This evidence concerns the gene IL2 and neoplasm.